- Home
- LMB vs CNTA Comparison
LMB vs CNTA Comparison
Compare LMB & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMB
- CNTA
- Stock Information
- Founded
- LMB 1901
- CNTA 2020
- Country
- LMB United States
- CNTA United Kingdom
- Employees
- LMB N/A
- CNTA N/A
- Industry
- LMB Engineering & Construction
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- LMB Consumer Discretionary
- CNTA Health Care
- Exchange
- LMB Nasdaq
- CNTA Nasdaq
- Market Cap
- LMB 1.6B
- CNTA 1.6B
- IPO Year
- LMB 2014
- CNTA 2021
- Fundamental
- Price
- LMB $149.20
- CNTA $14.07
- Analyst Decision
- LMB Strong Buy
- CNTA Strong Buy
- Analyst Count
- LMB 3
- CNTA 10
- Target Price
- LMB $136.67
- CNTA $28.78
- AVG Volume (30 Days)
- LMB 202.6K
- CNTA 1.2M
- Earning Date
- LMB 08-05-2025
- CNTA 08-12-2025
- Dividend Yield
- LMB N/A
- CNTA N/A
- EPS Growth
- LMB 31.50
- CNTA N/A
- EPS
- LMB 2.78
- CNTA N/A
- Revenue
- LMB $532,913,000.00
- CNTA $15,000,000.00
- Revenue This Year
- LMB $20.01
- CNTA N/A
- Revenue Next Year
- LMB $5.84
- CNTA N/A
- P/E Ratio
- LMB $53.67
- CNTA N/A
- Revenue Growth
- LMB 3.62
- CNTA 118.88
- 52 Week Low
- LMB $48.17
- CNTA $8.46
- 52 Week High
- LMB $154.05
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- LMB 66.47
- CNTA 60.47
- Support Level
- LMB $134.74
- CNTA $12.74
- Resistance Level
- LMB $143.00
- CNTA $14.27
- Average True Range (ATR)
- LMB 5.60
- CNTA 0.66
- MACD
- LMB -0.30
- CNTA 0.12
- Stochastic Oscillator
- LMB 77.34
- CNTA 85.57
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.